ReviewClinical chemistry2017
Biomarkers and Genetics in Peripheral Artery Disease.
Review in Clinical chemistry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- Role of noninvasive ocular imaging as a biomarker in peripheral artery disease (PAD): A systematic review.Vascular medicine (London, England) · 2024Pooled it
- Predictors of responders to mononuclear stem cell-based therapeutic angiogenesis for no-option critical limb ischemia.Stem cell research & therapy · 2019Trial
- Biomarker Analysis from the Compass Claudication Study - Rivaroxaban for Intermittent Claudication.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisTrial
- Association of the C-reactive protein-triglyceride-glucose index (CTI) with lower-extremity peripheral artery disease among U.S. adults.Atherosclerosis plus · 2026Article
- Variant-to-Biomarker Pathways in Peripheral Artery Disease: Multiomics Integration and Clinical Translation.Human mutation · 2026Review
- Dysregulation of circulating damage-associated molecular patterns in diabetic foot syndrome.Frontiers in immunology · 2026Article
- CARMN orchestrates angiogenesis from behind the opera scenes: signing love letters to the endothelium.The Journal of clinical investigation · 2025Article
- Multi-omics integration predicts 17 disease incidences in the UK Biobank.medRxiv : the preprint server for health sciences · 2025Article
- An evaluation of inflammatory and endothelial dysfunction markers as determinants of peripheral arterial disease in those with diabetes mellitus.Scientific reports · 2024Article
- Evaluation of Plasma Biomarkers for Causal Association With Peripheral Artery Disease.Arteriosclerosis, thrombosis, and vascular biology · 2024Article
- Article
- Causality of blood metabolites and metabolic pathways on peripheral arteriosclerosis: a Mendelian randomization study.Frontiers in nutrition · 2024Article
- Coronary Event Risk Test (CERT) as a Risk Predictor for the 10-Year Clinical Outcome of Patients with Peripheral Artery Disease.Journal of clinical medicine · 2023Article
- Role of G-Proteins and GPCRs in Cardiovascular Pathologies.Bioengineering (Basel, Switzerland) · 2023Review
- Ceramides in peripheral arterial plaque lead to endothelial cell dysfunction.JVS-vascular science · 2023Article
- IgG Glycosylation Profiling of Peripheral Artery Diseases with Lectin Microarray.Journal of clinical medicine · 2022Article
- The Genetic Architecture of the Etiology of Lower Extremity Peripheral Artery Disease: Current Knowledge and Future Challenges in the Era of Genomic Medicine.International journal of molecular sciences · 2022Review
- Cis-epistasis at the LPA locus and risk of cardiovascular diseases.Cardiovascular research · 2022Article
- Metabolic Biomarker Discovery for Risk of Peripheral Artery Disease Compared With Coronary Artery Disease: Lipoprotein and Metabolite Profiling of 31 657 Individuals From 5 Prospective Cohorts.Journal of the American Heart Association · 2021Article
- The Role of Circulating Biomarkers in Peripheral Arterial Disease.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
backgroundPeripheral artery disease (PAD) is highly prevalent and there is considerable diversity in the initial clinical manifestation and disease progression among individuals. Currently, there is no ideal biomarker to screen for PAD, to risk stratify patients with PAD, or to monitor therapeutic response to revascularization procedures. Advances in human genetics have markedly enhanced the ability to develop novel diagnostic and therapeutic approaches across a host of human diseases, but such developments in the field of PAD are lagging. CONTENT: In this article, we will discuss the epidemiology, traditional risk factors for, and clinical presentations of PAD. We will discuss the possible role of genetic factors and gene-environment interactions in the development and/or progression of PAD. We will further explore future avenues through which genetic advances can be used to better our understanding of the pathophysiology of PAD and potentially find newer therapeutic targets. We will discuss the potential role of biomarkers in identifying patients at risk for PAD and for risk stratifying patients with PAD, and novel approaches to identification of reliable biomarkers in PAD. SUMMARY: The exponential growth of genetic tools and newer technologies provides opportunities to investigate and identify newer pathways in the development and progression of PAD, and thereby in the identification of newer biomarkers and therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.